JCR Pharmaceuticals Co., Ltd. (TSE 4552) today announced the dosing of the first patient in its Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan. This marks a significant milestone for the company in the development of JR-142, a long-acting growth hormone therapy. The treatment is being evaluated for its effectiveness in pediatric patients with growth hormone deficiency.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) has announced the initiation of its Phase III clinical trial for JR-142 (INN: redalsomatropin alfa), a long-acting growth hormone therapy for pediatric patients with growth hormone deficiency. This marks a significant step forward in JCR’s efforts to improve treatment options for children with growth disorders. The trial, which involves 54 pediatric patients, will compare the efficacy of JR-142 to JCR’s current product, Growject®, and will run for 52 weeks, with growth outcomes as the primary measure of success. Additional trial details can be found on the Japan Register of Clinical Trials (jRCT2031240282).
Professor Noriyuki Namba, a key medical expert for the study from the Division of Pediatrics and Perinatology at Tottori University Faculty of Medicine, shared his enthusiasm for the development of JR-142, noting the significant potential it holds for pediatric patients. “Growth hormone therapy typically requires daily injections, but JR-142, as a long-acting therapy, offers the possibility of once-weekly dosing,” he explained. “This advancement could significantly ease the burden on children and their families, improving both convenience and quality of care while maintaining high safety standards.”
JR-142, a next-generation therapy, has been designed to provide long-lasting effects with a reduced frequency of injections, which could greatly benefit both patients and their families by reducing the daily burden of treatment. This development reflects JCR’s ongoing commitment to advancing therapies in the growth hormone field and offering patients more convenient and effective treatment options.
JCR Pharmaceuticals has been at the forefront of developing growth hormone therapies, with its existing product, Growject®, being a staple in pediatric treatment. Growject® was first launched in Japan in 1995 and is administered via subcutaneous injection 6–7 times a week, with the dosage adjusted based on the patient’s condition. JR-142, with its potential for once-weekly dosing, would represent a significant improvement in the lives of pediatric patients requiring growth hormone therapy.
In line with its mission to expand access to high-quality treatments, JCR Pharmaceuticals remains dedicated to ensuring a stable supply of these essential pharmaceuticals, while also addressing the diverse needs of patients with rare and genetic diseases. The company’s commitment to improving patients’ lives is reflected in its expanding global footprint and its focus on developing next-generation therapies to treat a variety of rare conditions.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company committed to improving the lives of patients with rare and genetic diseases. With a legacy of 49 years in Japan, JCR is expanding its presence in the US, Europe, and Latin America. The company develops and delivers next-generation therapies, focusing on rare diseases such as growth disorders, MPS II (Hunter syndrome), Fabry disease, and more. Through its innovative research and development, JCR aims to accelerate medical advancement and provide reliable, life-changing solutions for patients worldwide.
